Celgene (CELG -2.5%) slides on a UBS downgrade to Neutral on valuation this morning. The firm cites a lack of significant upside to its anemia drug Revlimid, saying the story has already "played itself out" since approval for the drug was shot down in the European Union.
Are you Bullish or Bearish on ?
Results for ()
Thanks for sharing your thoughts.
From other sites
at Investor's Business Daily (Fri, 6:51PM)
Biotech Stock Roundup: Pharmacyclics Up on Buyout Rumors, Celgene Drug Label Expanded - Analyst Blogat Zacks.com (Thu, 11:07AM)
at Nasdaq.com (Tue, 2:12PM)
at Zacks.com (Mon, 6:20PM)
at Benzinga.com (Feb 22, 2015)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs